Biosimilars in psoriasis 2015: what is next?

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology 2016-03, Vol.30 (3), p.467-469
Main Author: Puig, L.
Format: Article
Language:English
Subjects:
Biosimilar Pharmaceuticals - therapeutic use
Humans
Practice Guidelines as Topic
Psoriasis - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3633-60c1e49a6a7d2095d947e46345d27b8572754d9dbedbece2f3a05d562ff9417d3
cites cdi_FETCH-LOGICAL-c3633-60c1e49a6a7d2095d947e46345d27b8572754d9dbedbece2f3a05d562ff9417d3
container_end_page 469
container_issue 3
container_start_page 467
container_title Journal of the European Academy of Dermatology and Venereology
container_volume 30
creator Puig, L.
description
doi_str_mv 10.1111/jdv.12843
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1768562691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1768562691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3633-60c1e49a6a7d2095d947e46345d27b8572754d9dbedbece2f3a05d562ff9417d3</originalsourceid><addsrcrecordid>eNp1kMtOwkAUhidGI4gufAHTpSYW5j4dN0ZA8ULUGG-7ydCZxsGWYqcIvL3VAjtPTnJyku__Fj8Ahwi2UTWdsfluIxxRsgWaiPIoJDAi26AJJeahlEw2wJ73YwghQizaBQ3MSCQhxU1w2nW5d5lLdeEDNwmmPi-c9s4HGCJ2Fsw_dBlU38QuyvN9sJPo1NuD1W2Bl6vL5951OHwY3PQuhmFMOCEhhzGyVGquhcFQMiOpsJQTygwWo4gJLBg10oxstbHFCdGQGcZxkkiKhCEtcFx7p0X-NbO-VJnzsU1TPbH5zCskeFThXKIKPanRuMi9L2yipoXLdLFUCKrfclRVjvorp2KPVtrZKLNmQ67bqIBODcxdapf_m9Rt_3WtDOuE86VdbBK6-FRcEMHU2_1AdZ9w_5Hdvash-QFXIXqc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1768562691</pqid></control><display><type>article</type><title>Biosimilars in psoriasis 2015: what is next?</title><source>Wiley</source><creator>Puig, L.</creator><creatorcontrib>Puig, L.</creatorcontrib><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.12843</identifier><identifier>PMID: 25389042</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Biosimilar Pharmaceuticals - therapeutic use ; Humans ; Practice Guidelines as Topic ; Psoriasis - drug therapy</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2016-03, Vol.30 (3), p.467-469</ispartof><rights>2014 European Academy of Dermatology and Venereology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3633-60c1e49a6a7d2095d947e46345d27b8572754d9dbedbece2f3a05d562ff9417d3</citedby><cites>FETCH-LOGICAL-c3633-60c1e49a6a7d2095d947e46345d27b8572754d9dbedbece2f3a05d562ff9417d3</cites><orcidid>0000-0001-6083-0952</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25389042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Puig, L.</creatorcontrib><title>Biosimilars in psoriasis 2015: what is next?</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><subject>Biosimilar Pharmaceuticals - therapeutic use</subject><subject>Humans</subject><subject>Practice Guidelines as Topic</subject><subject>Psoriasis - drug therapy</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1kMtOwkAUhidGI4gufAHTpSYW5j4dN0ZA8ULUGG-7ydCZxsGWYqcIvL3VAjtPTnJyku__Fj8Ahwi2UTWdsfluIxxRsgWaiPIoJDAi26AJJeahlEw2wJ73YwghQizaBQ3MSCQhxU1w2nW5d5lLdeEDNwmmPi-c9s4HGCJ2Fsw_dBlU38QuyvN9sJPo1NuD1W2Bl6vL5951OHwY3PQuhmFMOCEhhzGyVGquhcFQMiOpsJQTygwWo4gJLBg10oxstbHFCdGQGcZxkkiKhCEtcFx7p0X-NbO-VJnzsU1TPbH5zCskeFThXKIKPanRuMi9L2yipoXLdLFUCKrfclRVjvorp2KPVtrZKLNmQ67bqIBODcxdapf_m9Rt_3WtDOuE86VdbBK6-FRcEMHU2_1AdZ9w_5Hdvash-QFXIXqc</recordid><startdate>201603</startdate><enddate>201603</enddate><creator>Puig, L.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6083-0952</orcidid></search><sort><creationdate>201603</creationdate><title>Biosimilars in psoriasis 2015: what is next?</title><author>Puig, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3633-60c1e49a6a7d2095d947e46345d27b8572754d9dbedbece2f3a05d562ff9417d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Biosimilar Pharmaceuticals - therapeutic use</topic><topic>Humans</topic><topic>Practice Guidelines as Topic</topic><topic>Psoriasis - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Puig, L.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Puig, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biosimilars in psoriasis 2015: what is next?</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2016-03</date><risdate>2016</risdate><volume>30</volume><issue>3</issue><spage>467</spage><epage>469</epage><pages>467-469</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>25389042</pmid><doi>10.1111/jdv.12843</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-6083-0952</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0926-9959
ispartof Journal of the European Academy of Dermatology and Venereology, 2016-03, Vol.30 (3), p.467-469
issn 0926-9959
1468-3083
language eng
recordid cdi_proquest_miscellaneous_1768562691
source Wiley
subjects Biosimilar Pharmaceuticals - therapeutic use
Humans
Practice Guidelines as Topic
Psoriasis - drug therapy
title Biosimilars in psoriasis 2015: what is next?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T04%3A58%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biosimilars%20in%20psoriasis%202015:%20what%20is%20next?&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Puig,%20L.&rft.date=2016-03&rft.volume=30&rft.issue=3&rft.spage=467&rft.epage=469&rft.pages=467-469&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.12843&rft_dat=%3Cproquest_cross%3E1768562691%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3633-60c1e49a6a7d2095d947e46345d27b8572754d9dbedbece2f3a05d562ff9417d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1768562691&rft_id=info:pmid/25389042&rfr_iscdi=true